Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.6B
29M shares
52-week range
$33.35 – $90.50
97% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NASDAQ
CS
Borrow rate
0.42%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $61.2M | $89.6M | $84.7M | $126.7M | $161.7M | $165.2M | $166.0M | $211.1M |
| Cost of revenue | $25.1M | $34.7M | $32.2M | $41.3M | $55.1M | $58.2M | $56.5M | $64.8M |
| Gross profit | $36.1M | $54.9M | $52.5M | $85.4M | $106.6M | $107.0M | $109.5M | $146.3M |
| Gross margin | 59.0% | 61.3% | 62.0% | 67.4% | 65.9% | 64.8% | 66.0% | 69.3% |
| R&D | $12.7M | $15.0M | $13.8M | $18.3M | $20.3M | $26.4M | $19.7M | $20.2M |
| Operating income | −$23.9M | −$30.9M | −$27.9M | −$25.1M | −$39.7M | −$65.0M | −$50.0M | −$39.0M |
| EBITDA | −$9.3M | −$25.5M | −$24.9M | −$26.5M | −$56.9M | −$58.3M | −$56.2M | −$22.3M |
| Net income | −$21.1M | −$38.1M | −$38.1M | −$41.1M | −$75.2M | −$78.5M | −$84.6M | −$51.1M |
| Net margin | -34.5% | -42.6% | -45.0% | -32.5% | -46.5% | -47.5% | -51.0% | -24.2% |
| EPS (diluted) | -1.22 | -1.86 | -1.63 | -1.72 | -3.08 | -3.07 | -3.00 | -1.72 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $267M | $-1.15 | $-1.29–$-1.07 | 4 |
| 2027 | $337M | $0.00 | $0.00–$0.01 | 4 |
| 2028 | $417M | $1.12 | $0.81–$1.99 | 9 |
| 2029 | $528M | $2.34 | $2.31–$2.38 | 3 |
Forward consensus · source: Financial Modeling Prep
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
establishmentlabs.comNo one on the platform currently holds ESTA.
No tracked institution reports a position in ESTA as of their last filing.
No one on the platform has traded ESTA yet.
| $1.5B |
| — |
| NVCRNovocure Ltd | $15.43 | +2.52% | $1.8B | — |
| SSIISS Innovations International, Inc. | $3.34 | -7.73% | $668M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at 14.5× sales vs its 8.8× historical median P/S.
Fair value ≈ $53.50 · price $88.62 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ESTA Establishment Labs® Appoints Taylor Harris to Board of Directors "Prior to Cutera, Mr. Harris served as Chief Financial Officer of MyoKardia, where he helped guide the company through its acquisition by Bristol Myers Squibb in a transaction valued at $13.1 billion." https://establishmentlabs2023cr.q4web.com/press-releases/press-releases-details/2026/Establishment-Labs-Appoints-Taylor-Harris-to-Board-of-Directors/default.aspx
View on StockTwits ↗$ESTA 10 year chart clear Double Top Needs to break that to move forward
View on StockTwits ↗$ESTA Establishment Labs® Added to Membership of U.S. Small-Cap Russell 2000® Index https://establishmentlabs2023cr.q4web.com/press-releases/press-releases-details/2026/Establishment-Labs-Added-to-Membership-of-U-S--Small-Cap-Russell-2000-Index/default.aspx
View on StockTwits ↗$ESTA setting up a sell the news event. Keep powder dry for the pullback. Consider even taking some gains at these levels. Overall
View on StockTwits ↗$ESTA bought a smidge more. This company is delivering on growth and research in a consistent manner and should be rewarded long term. Looking for either an acquisition over the next 18 months or the company to continue to go it alone and transform plastic surgery. Profitbility would easily be achieved after an acquisition. Each day this doesn’t happen makes Me want the company to continue to forge forward on its own. Easily worth $20B if they continue forward.
View on StockTwits ↗$OUST $ESTA thank you both for today. Strength is shown in times of weakness
View on StockTwits ↗$ESTA What do you think the future target is for end of this year? How high you think this stock can go.
View on StockTwits ↗$ESTA Establishment Labs (NASDAQ: ESTA) Buy (1) ESG Score: 48/100 Price Target: $100.00 (Prior $95.00) Plastic Surgeon KOL Roundtable Download - Part 2 THE TD COWEN INSIGHT Our bull thesis is that ESTA is not merely taking share; it is redefining the standard of care in augmentation around a branded, minimally invasive, premium patient experience enabled by revolutionary implant technology. We believe Motiva/Ergonomix implants combined with the Preservé and Mia MIS techniques have the potential to capture a majority share position and expand the breast implant TAM.
View on StockTwits ↗$ESTA Establishment Labs (NASDAQ: ESTA) Buy (1) ESG Score: 48/100 Price Target: $100.00 (Prior $95.00) Best Smidcap Ideas: ESTA-blishing a New Standard in Breast Augmentation THE TD COWEN INSIGHT We are elevating ESTA to our top Smidcap pick driven by the company's unique position as the only innovator in an otherwise commoditized market. Surgeon demand for the company's disruptive MIS procedural approaches and differentiated implant technologies alongside strong management execution underpin our confidence in the continuation of the beat-and-raise story. We raise our PT to $100.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.